1YangZ, MingXF. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 2006; 4: 53-65.
2Bauer V, Sotnikova R. Nitric oxide -- the endothelium-derived relaxing factor and its role in endothelial functions. Gen Physiol Biophys 2010; 29: 319-40.
3Stankevicius E, Kevelaitis E, Vainorius E, Simonsen U. Role of nitric oxide and other endothelium-derived factors. Medicina (Kaunas) 2003; 39: 333-41.
4Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.
5Drucker D J, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
6Meier J J, Nauck MA. Incretinsand the development of type 2 diabetes. Curr Diab Rep 2006; 6: 194-201.
7Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, etal. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-23.
8Briones M, Bajaj M. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. Expert Opin Pharmacother 2006; 7: 1055-64.
9Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vaso- relaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001; 102: 81-6.
10Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nystrom T. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Pept 2009; 157: 8-13.